Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study

Date
2020
Author
De Porre, Peter
Li, Susan
Mundle, Suneel
Tran, Namphuong
Fizazi, Karim
Matsubara, Nobuaki
Chi, Kim N.
ÖZGÜROĞLU, Mustafa
Rodriguez-Antolin, Alfredo
Feyerabend, Susan
Fein, Luis
Alekseev, Boris Y.
Sulur, Giri
Protheroe, Andrew
Metadata
Show full item record
Abstract
Background: LATITUDE, a randomized, double-blind trial, compared abiraterone acetate and prednisone (AAP) + androgen deprivation therapy (ADT) versus placebo (PBO) + ADT in high-risk metastatic castration-sensitive prostate cancer (mCSPC).
URI
http://hdl.handle.net/20.500.12627/5576
https://doi.org/10.1016/j.eururo.2019.11.021
Collections